Dataset related to article "Real-life Effectiveness and Safety of Risankizumab in Moderateto- severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study"
Authors/Creators
- 1. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI) AND Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI)
- 2. Psocare Unit, IRCCS Policlinico San Donato, San Donato Milanese (MI)
- 3. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI) AND Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (MI))
- 4. IRCCS Humanitas Research Hospital, Rozzano (MI)
- 5. Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI)
- 6. Clinica Dermatologica Universitaria di Torino, ASO Città della Salute e della Scienza, Turin, Italy
Description
This record contains data related to article "Real-life Effectiveness and Safety of Risankizumab in Moderateto- severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study"
Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in monotherapy up to week 40 in a “real-life” setting. At week 40, 98.7%, 85.7% and 62.3% of patients achieved a Psoriasis Area and Severity Index (PASI) reduction ≥ 75% (PASI 75), PASI 90 and PASI 100, respectively. Patients who had not responded to 2 or more previous biologic treatments were significantly less likely to achieve PASI 75/90 at week 16 and PASI 90/100 at week 40 compared
with those who had been previously treated with
only 1 biologic, and compared with those treated with risankizumab as a first-line biologic. Increasing body mass index decreased the chances of reaching PASI 90 at week 40. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment. These data suggest that the efficacy of risankizumab for plaque psoriasis in “real-life” clinical practice could differ from pivotal clinical trials data.
Files
Restricted
The record is publicly accessible, but files are restricted. <a href="https://zenodo.org/account/settings/login?next=https://zenodo.org/records/5749506">Log in</a> to check if you have access.
Request access
If you would like to request access to these files, please fill out the form below.
You need to satisfy these conditions in order for this request to be accepted:
This set of data is accessible only upon request because it includes sensitive data.
Please write your request to biblioteca@humanitas.it
You are currently not logged in. Do you have an account? Log in here
Additional details
Related works
- Is supplement to
- 10.2340/actadv.v101.283 (DOI)
- 34596230 (PMID)